Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance

Cell Reports(2019)10.1016/j.celrep.2019.02.023Source: DataRank Database

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance is a research paper published in Cell Reports (2019). On theSindex it has a DataRank of 0.742. It has been cited 140 times.

N/A

0.742DataRank · unranked

Scored on demand from live citation data

140 citations

Free full text

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 11.79)OA: goldTopics (51)Linked Datasets (6)DataCite Reuse (6)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (0/2)

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.742

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (5)

Seth A. Wander ORCID,Tanvi Visal,Nikhil Wagle ORCID,Geoffrey I. Shapiro ORCID,Liam Cornell

Live enrichment

PubMed:30840889 OpenAlex:https://openalex.org/W2918928681

National Institutes of Health

Grant: P50 CA168504

American Association for Cancer Research

Grant: 1620-38-WAGL

National Institutes of Health

Grant: 5T32CA009172-21

GRADUATE TRAINING IN CANCER RESEARCH

National Institutes of Health

Grant: 5P50CA168504-03

Overcoming Resistance to Standard HER2-Directed Therapies for Breast Cancer

NCI NIH HHS

Grant: T32 CA009172

FWCI

11.79

Citation Percentile

1.0%

Citation Trend

2019

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttp://www.cell.com/article/S2211124719301937/pdf

publisherhttp://www.cell.com/article/S2211124719301937/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2211124719301937?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124719301937?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.celrep.2019.02.023

Fields of Study

Advanced Breast Cancer TherapiesCancer-related Molecular PathwaysLung Cancer Research Studies0301 basic medicine0303 health sciences03 medical and health sciencesAnimalsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6HumansMicroRNAsTransforming Growth Factor beta

MeSH Terms

AnimalsHumansTransforming Growth Factor betaMicroRNAsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6

Keywords

PalbociclibCyclin-dependent kinase 6Cancer researchBreast cancermicroRNAEstrogen receptorSignal transductionCancerBiologyMedicinePhenotypeCell cycleInternal medicineCyclin-dependent kinaseCell biologyMetastatic breast cancerGeneGeneticsMicroRNAsQH301-705.5Transforming Growth Factor betaAnimalsCyclin-Dependent Kinase 4HumansBiology (General)ArticleCDK6SMAD4TGF-βdrug resistanceexosomesribociclibtargeted therapy

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer

10.6084/m9.figshare.25963049.v1figshare

Additional file 1 of Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer

10.6084/m9.figshare.25963049figshare

Additional file 2 of Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer

10.6084/m9.figshare.25963250.v1figshare

Additional file 2 of Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer

10.6084/m9.figshare.25963250figshare

Additional file 3 of Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer

10.6084/m9.figshare.26728945.v1figshare

Additional file 3 of Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer

10.6084/m9.figshare.26728945figshare

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance

FAIR Checklist

DataRank Breakdown

Authors (5)

Funding (5 grants)

Impact

Open Access

Topics

Linked Datasets (6)